August 22, 2020 : Issue #1056

TOP STORIES — Diabetes News and Research

Vitamin D Supplementation Reduces the Risk of T2DM

Risks Associated with Age of Diabetes Onset

Metformin Reduces Presurgical Stress

This week we have a great study for you. Our intern Joan Prifti, PharmD. Candidate, LECOM College of Pharmacy, has real clinical data on the use of an over the counter product, that you can get on Amazon or at the pharmacy for less than $15 a month, that can lower FPG and A1c and prevent the development of type 2 diabetes.

Usually these kinds of claims are published in unheard-of journals and only contained a few people. However, this study had over 43,000 participants and was published in the Journal of Clinical Endocrinology & Metabolism.

To find out what this $15 product is and what it did, be sure to read this week’s LaterPay article.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

Large study finds both vitamin D dosage and patient BMI play a role in the effectiveness of supplementation in preventing T2DM. 

Compelling evidence suggests that the age of diabetes diagnosis may be linked to the risk of end-stage kidney disease. 

Metformin was used to reduce the risk of complications associated with surgery in type 2 diabetes patients. 

A recent study examined the relationship between sleep disorders and the risk of dementia in patients with newly diagnosed type 2 diabetes, and found sleep disorders had differential effects on subtypes of dementia. Sleep disorders increased the risk of Alzheimer’s disease but did not influence vascular dementia. Significant positive association between sleep disorders and Alzheimer’s disease was well established, but previous evidence for vascular dementia was unclear.

In the patients with type 2 diabetes with age range 42-84 (M=57.8, SD=9.5), this study identified 2,059 events of dementia during an average follow-up time of 5.7 years. In patients with type 2 diabetes, subjects with sleep disorders were associated with an increased risk of all-cause dementia, Alzheimer’s disease, and other dementias compared to those without sleep disorders. This study used the Korean Health Screening Cohort data and included 39,135 subjects aged ≥40 years with new-onset type 2 diabetes between 2004 and 2007, with follow-up throughout 2013. Sleep disorders were measured by ICD-10 code as a primary diagnosis, and the adjusted hazard ratio (AHR) and 95% CI of all-cause dementia, Alzheimer’s disease, vascular dementia, and other dementia were estimated using multivariable Cox proportional hazards regression models.

These findings suggest that sleep disorders are significantly associated with an increased risk of dementia in patients with new-onset type 2 diabetes.

J Diabetes. 2020 July 18. doi: 10.1111/1753-0407.13092. Online ahead of print

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Brianna Belton, PharmD. Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Bernice Ford, 2021 PharmD Candidate, Florida Agricultural & Mechanical University, College of Pharmacy and Pharmaceutical Sciences

Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy

Lawand Kamal, PharmD Candidate 2021, Skaggs School of Pharmacy and Pharmaceutical Sciences

Sameen Khan, Pharm.D. Candidate, USF College of Pharmacy  

Joan Prifti, PharmD. Candidate, LECOM College of Pharmacy 

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com